Your browser doesn't support javascript.
loading
Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer.
Jayakrishnan, Thejus; Mariam, Arshiya; Farha, Nicole; Rotroff, Daniel M; Aucejo, Federico; Barot, Shimoli V; Conces, Madison; Nair, Kanika G; Krishnamurthi, Smitha S; Schmit, Stephanie L; Liska, David; Khorana, Alok A; Kamath, Suneel D.
Afiliação
  • Jayakrishnan T; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
  • Mariam A; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA.
  • Farha N; Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, USA.
  • Rotroff DM; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
  • Aucejo F; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA.
  • Barot SV; Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, USA.
  • Conces M; Department of Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, USA.
  • Nair KG; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
  • Krishnamurthi SS; Case Comprehensive Cancer Center, Cleveland, USA.
  • Schmit SL; Case Comprehensive Cancer Center, Cleveland, USA.
  • Liska D; Department of Hematology-Oncology, University Hospital Seidman Cancer Center, Cleveland, USA.
  • Khorana AA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
  • Kamath SD; Case Comprehensive Cancer Center, Cleveland, USA.
Sci Rep ; 14(1): 4294, 2024 02 21.
Article em En | MEDLINE | ID: mdl-38383634
ABSTRACT
Deleterious effects of environmental exposures may contribute to the rising incidence of early-onset colorectal cancer (eoCRC). We assessed the metabolomic differences between patients with eoCRC, average-onset CRC (aoCRC), and non-CRC controls, to understand pathogenic mechanisms. Patients with stage I-IV CRC and non-CRC controls were categorized based on age ≤ 50 years (eoCRC or young non-CRC controls) or  ≥ 60 years (aoCRC or older non-CRC controls). Differential metabolite abundance and metabolic pathway analyses were performed on plasma samples. Multivariate Cox proportional hazards modeling was used for survival analyses. All P values were adjusted for multiple testing (false discovery rate, FDR P < 0.15 considered significant). The study population comprised 170 patients with CRC (66 eoCRC and 104 aoCRC) and 49 non-CRC controls (34 young and 15 older). Citrate was differentially abundant in aoCRC vs. eoCRC in adjusted analysis (Odds Ratio = 21.8, FDR P = 0.04). Metabolic pathways altered in patients with aoCRC versus eoCRC included arginine biosynthesis, FDR P = 0.02; glyoxylate and dicarboxylate metabolism, FDR P = 0.005; citrate cycle, FDR P = 0.04; alanine, aspartate, and glutamate metabolism, FDR P = 0.01; glycine, serine, and threonine metabolism, FDR P = 0.14; and amino-acid t-RNA biosynthesis, FDR P = 0.01. 4-hydroxyhippuric acid was significantly associated with overall survival in all patients with CRC (Hazards ratio, HR = 0.4, 95% CI 0.3-0.7, FDR P = 0.05). We identified several unique metabolic alterations, particularly the significant differential abundance of citrate in aoCRC versus eoCRC. Arginine biosynthesis was the most enriched by the differentially altered metabolites. The findings hold promise in developing strategies for early detection and novel therapies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Metabolômica Limite: Humans / Middle aged Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Metabolômica Limite: Humans / Middle aged Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos